Loading...
Market
What will be the outcome of GSK's CMG1A46 acquisition by end of 2026?
2
Resolution / Starting Odds
Successful market introduction • 25%
Delayed market introduction • 25%
Project discontinued • 25%
Acquisition divested • 25%
GSK financial reports, press releases, and industry analysis
Story
British GSK Acquires Experimental Lupus Drug from Chimagen Biosciences for Up to $850 Million
Oct 29, 2024, 12:27 PM
British drugmaker GSK has entered into an agreement to acquire CMG1A46, an experimental drug from Chinese biotech firm Chimagen Biosciences, for up to $850 million. This acquisition includes a $300 million upfront payment and aims to expand GSK's pipeline of potential treatments for lupus. The drug, CMG1A46, is a clinical-stage dual CD19 and CD20-targeted T cell-engager, which is expected to enhance GSK's immunology portfolio.
View original story
Similar markets
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Major acquisition by competitor • 25%
New drug development announced • 25%
Price reduction of existing drugs • 25%
No significant response • 25%
Less than $100 million • 25%
$100 million - $200 million • 25%
$200 million - $300 million • 25%
More than $300 million • 25%
Increase by over 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Significant efficacy • 25%
Moderate efficacy • 25%
No efficacy • 25%
Inconclusive results • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%